Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 606 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05779605Recruiting
Online rehab for lymphoma survivors after chemotherapy
This trial tests a telerehabilitation (remote exercise/rehab) program for people with recent lymphoma or other blood cancers after chemotherapy. It aims to improve recovery and fitness while monitoring safety through an exercise test and check-ins.
BrnoAges 18 years+ - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05807789Recruiting
Genetic testing during CAR-T treatment for adults
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Bologna, ItalyAges 18–70 - NCT05846763Recruiting
Obinutuzumab plus lenalidomide for returning follicular lymphoma
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
TianjinAges 18 years+ - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT05849207RecruitingPhase 1
Cyclophosphamide after transplant for people 65 and older
This early-phase study tests giving cyclophosphamide after a specific type of stem cell transplant (haploidentical) in people age 65 and older. It aims to improve transplant safety and outcomes by adjusting medicine given after the graft is placed.
Los Angeles, CaliforniaAges 65 years+ - NCT05866757Recruiting
Stopping maintenance treatment in multiple myeloma patients
This study looks at whether it is safe to stop “maintenance” treatment for people with multiple myeloma who have been in remission for a long time, including those who stopped early because of side effects. It tests whether stopping therapy affects disease control and helps reduce ongoing treatment burden.
Cork, IrelandAges 18 years+ - NCT05870475RecruitingPhase 2
Interferon plus ruxolitinib for hydroxyurea-resistant polycythemia vera
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
TianjinAges 18 years+ - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05908409RecruitingPhase 1/Phase 2
Testing an investigational drug for blood cancers that came back
This Phase 1/2 trial tests IDP-121 in people with certain blood cancers that have returned or did not respond to available treatments. The goal is to find a safe dose and see whether the treatment can help control the cancer.
Santander, CantabriaAges 18 years+ - NCT05913804RecruitingPhase 1
Study of YTS104 cell therapy for hard-to-treat myeloma
This Phase 1 study tests an injected cell therapy (YTS104) for people with multiple myeloma that has come back or did not respond after several prior treatments. The goal is to see whether the treatment is safe and may help control the disease.
TianjinAges 18–75 - NCT05914662RecruitingPhase 2
Zanubrutinib plus BR for newly diagnosed symptomatic WM
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05942885Recruiting
Hypnosis for calming anxiety in lymphoma patients
This trial studies whether hypnosis can help reduce anxiety. It is meant for adults with certain types of lymphoma who are newly told their diagnosis and have anxiety symptoms.
Lyon, Pierre-BéniteAges 18 years+ - NCT05943067RecruitingPhase 1/Phase 2
Test of donor immune cells after stem cell transplant to prevent relapse
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
TübingenAges 2 months–65 years - NCT05949125RecruitingPhase 1
CD123-positive AML trial testing an immune cell treatment
This Phase 1 trial tests an allogeneic immune-cell therapy for adults with CD123-positive acute myeloid leukemia (AML) that has not responded well to standard treatments. It aims to see whether this treatment can control leukemia after medicines and possibly transplant options are no longer suitable.
Ulm, Baden-WurttembergAges 18 years+ - NCT05950750Recruiting
Living with aTTP? Join a national patient registry study
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
AnkaraAges 18 years+ - NCT05956457Recruiting
Using wearable and PRO check-ins for relapsed myeloma
This study uses your self-reported symptoms (PRO) and wearable/device data to help improve care for people with relapsed multiple myeloma who are starting new treatment. It may help by providing insights about how you’re doing during therapy—without changing your cancer treatment in a study-specific way.
Seattle, WashingtonAges 18 years+ - NCT05958719RecruitingPhase 2
Chidamide plus chemotherapy for new nodal TFH cell lymphoma
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05979363RecruitingPhase 2
CAR-T cell therapy for plasma cell leukemia patients
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
TianjinAges 18–75 - NCT05979675Recruiting
Acute Myeloid Leukemia Patient Registry
This registry collects information from adults with AML diagnosed since 2020. It helps doctors understand and improve treatment for this blood cancer.
AntalyaAges 18 years+ - NCT05982249Recruiting
Hypnosis and virtual reality for bone marrow exam
This trial tests combining hypnosis with virtual reality to help relax patients during a bone marrow exam. It may offer a gentler, drug-free way to manage discomfort.
HaifaAges 18 years+ - NCT05983952RecruitingPhase 2
Anti-CD38 antibody for APS with low platelets
This trial tests an anti-CD38 antibody in people with antiphospholipid syndrome (APS) who have very low platelet counts and haven't improved with steroids or other treatments. The goal is to see if it can safely raise platelet levels.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 606 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.